A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

Clinical trial NCT06682988 · RECRUITING

Trial details

NCT number: NCT06682988
Sponsor: AbbVie
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Advanced High-Grade Epithelial Ovarian Cancer Primary Peritoneal Cancer Fallopian Tube Cancers

Start date: 2025-05-28
Primary completion: 2026-07-01
Enrollment: 110

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.